Carregando empresa
ONCBeone Medicines Ltd.US$ 48BA+As participações na receita são estimativas para fiscal year ended 2025-11-30, high confidence, não números de um relatório oficial.
Bexobrutideg (NX-5948)
An experimental oral medicine designed to make cells remove Bruton tyrosine kinase, a protein involved in some blood cancers. It is being tested in patients with blood cancers, including chronic lymphocytic leukemia.
NX-1607
An experimental oral medicine that blocks CBL-B, a cell protein that restrains immune cells. It is being tested to help immune cells attack tumors.
Zelebrudomide (NX-2127)
An experimental oral medicine designed to remove Bruton tyrosine kinase and two proteins involved in immune-cell activity. Nurix discontinued further clinical development; some patients already receiving it may continue treatment.
NX-0479 / GS-6791
A partner-developed experimental medicine designed to degrade IRAK4, a protein involved in inflammation.
Demonstrações financeiras completas →
Nurix develops experimental medicines designed to make cells remove disease-related proteins, rather than simply block them. Its discovery system uses machine learning and large chemical libraries to find starting points for drugs. Pharmaceutical partners pay for research and rights to drug candidates; Nurix also develops some candidates itself. It has no approved medicines for sale.
Construído a partir dos próprios documentos de Nurix Therapeutics, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
The themes Nurix Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$ 16,33+2,8%fechamento 11 de nov.
Números até 31 de agosto de 2026, do 10-Q arquivado em 13 de outubro de 2026
Nurix licenses rights to experimental cancer drugs and protein-degradation research to pharmaceutical companies, while developing its own cancer and immune-disease medicines.
Grade A+
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Mostrando 2 de 23 trimestres do histórico de notas de Nurix Therapeutics, Inc.. Os outros 21 vão até abril de 2021.
